SCHEMBL3855485

SCHEMBL3855485

Cc1c(C[C@H](N)C(=O)OCl)c2ccccc2n1Cc1ccc(OC(F)(F)F)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G2A P14555 11/20 0.50
PPARG P37231 1/20 0.46
HDAC1 Q13547 2/20 0.45
HDAC6 Q9UBN7 2/20 0.45
PTGDR2 Q9Y5Y4 1/20 0.45
PLA2G1B P04054 1/20 0.43
ADAM17 P78536 1/20 0.43
GFER P55789 1/20 0.43
THRA P10827 1/20 0.43
THRB P10828 1/20 0.43
KDM4E B2RXH2 2/20 0.41
LMNA P02545 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
TSHR P16473 1/20 0.41
CYP2C19 P33261 1/20 0.41
BLM P54132 1/20 0.41
PMP22 Q01453 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3858093 0.92 PLA2G2A (0.48) PLA2G2APPARGHDAC1HDAC6PTGDR2
SCHEMBL3853781 0.88 HDAC1 (0.49) PLA2G2APPARGHDAC1HDAC6PTGDR2
SCHEMBL3848975 0.87 LMNA (0.55) PLA2G2AHDAC1HDAC6PTGDR2GFER
SCHEMBL3857024 0.87 HDAC1 (0.51) PLA2G2AHDAC1HDAC6PTGDR2GFER
SCHEMBL3848774 0.86 HDAC1 (0.50) PLA2G2AHDAC1HDAC6PTGDR2GFER
SCHEMBL3855493 0.82 ADAM17 (0.54) PLA2G2APPARGHDAC1HDAC6PTGDR2
SCHEMBL3855489 0.82 ADAM17 (0.54) PLA2G2APPARGHDAC1HDAC6PTGDR2
SCHEMBL3849885 0.82 PLA2G2A (0.49) PLA2G2APPARGCYP1A2CYP2C9CYP2C19
SCHEMBL3848949 0.82 HDAC1 (0.47) PLA2G2AHDAC1HDAC6PTGDR2ADAM17
SCHEMBL3854421 0.80 HDAC1 (0.48) PLA2G2APPARGHDAC1HDAC6PTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7576222-B2 N-{[4-(but-2-ynyloxy)phenyl]sulfonyl}-1-(2-fluorobenzyl)-5-methoxy-2-methyltryptophan; for treatment of rheumatoid arthritis, juvenile rheumatoid arthritis, ulcerative colitis, or Crohn's disease WYETH (US) 2009-08-18 US disclosed
US-20060160884-A1 Alkynyl-containing tryptophan derivative inhibitors of tace/matrix metalloproteinase WYETH (US) 2006-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160884-A1 Alkynyl-containing tryptophan derivative inhibitors of tace/matrix metalloproteinase ADAM17, TPSAB1, ADAM10 PLA2G2A 3197/4885PPARG 4511/4885HDAC1 589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.